Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT04778267 |
Other study ID # |
MD-342-2020 |
Secondary ID |
|
Status |
Completed |
Phase |
Phase 4
|
First received |
|
Last updated |
|
Start date |
March 12, 2021 |
Est. completion date |
March 10, 2023 |
Study information
Verified date |
March 2023 |
Source |
Kasr El Aini Hospital |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Erector spinae plane block (ESPB) is a new evolving fascial pain block in the era of regional
anaesthesia. ESPB was applied in varieties of surgeries and provided an eminent role in
trauma patient especially those with fracture ribs. ESPB exhibits simple, safe and easy
technique with minimal or no sympathetic blockade effects, thus gaining popularity in wide
range of surgeries. The optimum effective dose of local anaesthetic, the effective volume of
drug used for desired dermatomes. Comparison with different regional blocks is preferable to
know the optimum analgesic technique for those population of patients (4). Many studies have
already compared solo ESPB with thoracic epidural analgesia (TEA), thoracic paravertebral
block (TPVB), serratus anterior plane block (SAPB) and pectoral nerves block. Only few case
reports described the combination effect of rhomboid intercostal, transversus thoracic muscle
and parasternal plane blocks to ESPB in modified radical mastectomy.
Description:
patients scheduled for modified radical mastectomy and axillary dissection under general
anesthesia (GA) will be included in the study. The patients will be randomly allocated by a
computer-generated table into one of the two study groups.Thoracic paravertebral block group
(TPV group) and combined erector spinae and pecto-intercostal fascial plane blocks group
(ES-PI group).
0.25% bupivacaine and 1 mg dexamethasone will be injected with different volumes in each
block.
The first time to ask for rescue analgesia post-operatively will be measured. Using MedCalc
Software version 14 (MedCalc Software bvba, Ostend, Belgium), 24 patients (12 patients per
group) were calculated for a relative difference of 10% (0.635 hours) in the time to first
analgesic request between both groups, with a study power of 95% and an alpha error of 0.05.
This number will be increased to 30 patients (15 patients per group) to compensate for
possible dropouts.
Analysis of data will be performed using the Statistical Package for Social Science (SPSS)
software, version 21 for Microsoft Windows (SPSS Inc., Chicago, iL, USA). Categorical data
will be reported as numbers and percentages and will be analyzed using the chi-squared test.
Continuous data will be checked for normality using the Kolmogorov-Smirnov test. Normally
distributed data will be presented as means (standard deviations) and will be analyzed using
the unpaired student t-test. Skewed data will be expressed as medians(quartiles) and will be
analyzed using the Mann Whitney U test. For repeated measures, a two-way repeated measures
ANOVA will be used to evaluate block (between-groups factor) and time (repeated measures)".
Post-hoc pairwise comparison will be performed using the Bonferroni test. A P value of 0.05
or less will be considered significant.